Lipid lowering to delay the progression of coronary artery disease

Por Feher, Michael D
Publicado em 2003

Authors' response

Por Munro, Neil, Feher, Michael
Publicado em 2008

Current, new, and emerging therapies for managing hyperglycaemia in type 2 diabetes

Por Munro, Neil, Feher, Michael D
Publicado em 2008

Persistent hypertriglyceridemia in statin-treated patients with type 2 diabetes mellitus

Por Feher, Michael, Greener, Mark, Munro, Neil
Publicado em 2013

Prediction of cardiovascular risk : Program is not suitable for diabetic patients

Por Zambanini, Andrew, Smith, Martin R, Feher, Michael D
Publicado em 1999

Does Real World Use of Liraglutide Match its Use in the LEADER Cardiovascular Outcome Trial? Study Protocol

Por Hinton, William, Feher, Michael, Munro, Neil, de Lusignan, Simon
Publicado no Diabetes Ther (2018)

Sodium-Glucose Co-Transporter-2 (SGLT2) Inhibitors: Comparing Trial and Real World Use (Study Protocol)

Por McGovern, Andrew, Feher, Michael, Munro, Neil, de Lusignan, Simon
Publicado no Diabetes Ther (2017)

Sodium-Glucose Co-transporter 2 (SGLT2) Inhibitor: Comparing Trial Data and Real-World Use

Por McGovern, Andrew, Feher, Michael, Munro, Neil, de Lusignan, Simon
Publicado no Diabetes Ther (2017)

How Generalizable Are Cardiovascular Outcome Trials of Sodium-Glucose Co-Transporter-2 Inhibitors? A National Database Study: Study Protocol

Por Hinton, William, Feher, Michael D., Munro, Neil, de Lusignan, Simon
Publicado no Diabetes Ther (2019)

Variation in the diagnosis and control of hypertension is not explained by conventional variables: Cross-sectional database study in English general practice

Por Coyle, Rachel, Feher, Michael, Jones, Simon, Hamilton, Mark, de Lusignan, Simon
Publicado no PLoS One (2019)

Patients' with type 2 diabetes willingness to pay for insulin therapy and clinical outcomes

Por Feher, Michael D, Brazier, John, Schaper, Nicolaas, Vega-Hernandez, Gabriela, Nikolajsen, Annie, Bøgelund, Mette
Publicado no BMJ Open Diabetes Res Care (2016)

Intensification to injectable therapy in type 2 diabetes: mixed methods study (protocol)

Por de Lusignan, Simon, Hinton, William, Konstantara, Emmanouela, Munro, Neil, Whyte, Martin, Mount, Julie, Feher, Michael
Publicado no BMC Health Serv Res (2019)

Effectiveness of Liraglutide and Lixisenatide in the Treatment of Type 2 Diabetes: Real-World Evidence from The Health Improvement Network (THIN) Database in the United Kingdom

Por Feher, Michael, Vega-Hernandez, Gabriela, Mocevic, Emina, Buysse, Brian, Myland, Melissa, Power, Geraldine S., Nystrup Husemoen, Lise L., Kim, Joseph, Witte, Daniel R.
Publicado no Diabetes Ther (2017)

Paraoxonase-1 Is Not Associated with Coronary Artery Calcification in Type 2 Diabetes: Results from the PREDICT Study

Por Mackness, Bharti, Marsillach, Judit, Elkeles, Robert S., Godsland, Ian F., Feher, Michael D., Rubens, Michael B., Flather, Marcus D., Humphries, Steve E., Cooper, Jackie, Mackness, Mike
Publicado em 2012